Cyclophosphamide

Generic Name
Cyclophosphamide
Brand Names
Procytox
Drug Type
Small Molecule
Chemical Formula
C7H15Cl2N2O2P
CAS Number
50-18-0
Unique Ingredient Identifier
6UXW23996M
Background

Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication

Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions
Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
Associated Therapies
-
Clinical Trials
Related News

Natural Killer(NK) Cell Therapy for AML Minimal Residual Disease

First Posted Date
2022-11-01
Last Posted Date
2024-11-06
Lead Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Target Recruit Count
1
Registration Number
NCT05601830
Locations
🇨🇳

Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China

A Trial Comparing Unrelated Donor BMT with IST for Pediatric and Young Adult Patients with Severe Aplastic Anemia (TransIT, BMT CTN 2202)

First Posted Date
2022-10-31
Last Posted Date
2024-11-08
Lead Sponsor
Boston Children's Hospital
Target Recruit Count
234
Registration Number
NCT05600426
Locations
🇺🇸

University of Alabama at Birmingham, Birmingham, Alabama, United States

🇺🇸

Phoenix Children's Hospital, Phoenix, Arizona, United States

🇺🇸

Arkansas, Little Rock, Arkansas, United States

and more 46 locations

Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma

First Posted Date
2022-10-31
Last Posted Date
2023-06-07
Lead Sponsor
Joseph Tuscano
Target Recruit Count
24
Registration Number
NCT05600686
Locations
🇺🇸

University of California Davis Comprehensive Cancer Center, Sacramento, California, United States

Relmacabtagene Autoleucel as First-Line Therapy for High-Risk Large B-Cell Lymphoma

First Posted Date
2022-10-21
Last Posted Date
2024-01-08
Lead Sponsor
Peking University Cancer Hospital & Institute
Target Recruit Count
20
Registration Number
NCT05590221
Locations
🇨🇳

Henan Cancer Hospital, Zhengzhou, Henan, China

🇨🇳

Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China

🇨🇳

Peking University International Hospital, Beijing, Beijing, China

and more 1 locations

Autologous T Cells Targeting HPV16 HPV18 & Survivin in Patients With R/R HPV-related Oropharyngeal Cancers

First Posted Date
2022-10-17
Last Posted Date
2024-01-16
Lead Sponsor
NexImmune Inc.
Target Recruit Count
36
Registration Number
NCT05582590

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy

First Posted Date
2022-10-17
Last Posted Date
2024-12-27
Lead Sponsor
Fudan University
Target Recruit Count
716
Registration Number
NCT05582499
Locations
🇨🇳

Fudan University Shanghai Cancer Center Shanghai, China, 200032, Shanghai, Shanghai, China

Intestinal Microbiota Impact for Prognosis and Treatment Outcomes in Early Luminal Breast Cancer and Pancreatic Cancer Patients

First Posted Date
2022-10-14
Last Posted Date
2022-10-14
Lead Sponsor
Moscow Clinical Scientific Center
Target Recruit Count
35
Registration Number
NCT05580887
Locations
🇷🇺

Moscow Clinical Scientific Center named after AS Loginov, Moscow, Not Required, Russian Federation

A Phase II Pediatric Study of a Graft-VS.-Host Disease (GVHD) Prophylaxis Regimen With no Calcineurin Inhibitors After Day +60 Post First Allogeneic Hematopoietic Cell Transplant for Hematological Malignancies

First Posted Date
2022-10-14
Last Posted Date
2024-07-10
Lead Sponsor
St. Jude Children's Research Hospital
Target Recruit Count
3
Registration Number
NCT05579769
Locations
🇺🇸

St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Anti-BCMA Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple Myeloma

First Posted Date
2022-10-13
Last Posted Date
2024-05-03
Lead Sponsor
Thomas Martin, MD
Target Recruit Count
5
Registration Number
NCT05577000
Locations
🇺🇸

University of California, San Francisco, San Francisco, California, United States

A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

First Posted Date
2022-10-13
Last Posted Date
2024-12-04
Lead Sponsor
Genmab
Target Recruit Count
900
Registration Number
NCT05578976
Locations
🇺🇸

Orlando Health Cancer Institute /ID# 232626, Orlando, Florida, United States

🇺🇸

University of Illinois at Chicago /ID# 226889, Chicago, Illinois, United States

🇺🇸

University of Maryland, Baltimore /ID# 225421, Baltimore, Maryland, United States

and more 326 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy